Sean Toenjes PhD

Sean Toenjes is Executive Director of Chemistry and Innovation at Aethon Therapeutics, focused on extending Aethon’s approach to new targets by using the HapImmune platform to guide chemistry design. Sean received his B.S. in Chemistry at the University of Illinois Urbana-Champaign and earned his Ph.D. in Organic Chemistry at San Diego State University (Gustafson Lab), where he developed methodologies to access atropisomeric compounds and leveraged atropisomerism to increase kinase inhibitor selectivity. During his postdoc at Stanford University (Gray Lab), Sean developed covalent E3 ligase binders and bivalent degraders.